166 related articles for article (PubMed ID: 22716255)
21. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific membrane antigen expression in melanoma metastases.
Snow H; Hazell S; Francis N; Mohammed K; O'Neill S; Davies E; Mansfield D; Messiou C; Hujairi N; Nicol D; Harrington K; Smith M
J Cutan Pathol; 2020 Dec; 47(12):1115-1122. PubMed ID: 32529651
[TBL] [Abstract][Full Text] [Related]
23. Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Crende O; Sabatino M; Valcárcel M; Carrascal T; Riestra P; López-Guerrero JA; Nagore E; Mandruzzato S; Wang E; Marincola FM; Vidal-Vanaclocha F
Am J Pathol; 2013 Jul; 183(1):69-82. PubMed ID: 23707237
[TBL] [Abstract][Full Text] [Related]
24. EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma.
Caudron A; Battistella M; Feugeas JP; Pages C; Basset-Seguin N; Mazouz Dorval S; Funck Brentano E; Sadoux A; Podgorniak MP; Menashi S; Janin A; Lebbé C; Mourah S
Exp Dermatol; 2016 Aug; 25(8):618-22. PubMed ID: 27060463
[TBL] [Abstract][Full Text] [Related]
25. Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma.
Sargen MR; Cloutier JM; Sarin KY; Rieger KE; Chu P; Swetter SM; Novoa RA
Pigment Cell Melanoma Res; 2019 May; 32(3):474-478. PubMed ID: 30672662
[No Abstract] [Full Text] [Related]
26. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
De Vries TJ; De Wit PE; Clemmensen I; Verspaget HW; Weidle UH; Bröcker EB; Ruiter DJ; Van Muijen GN
J Pathol; 1996 Jul; 179(3):260-5. PubMed ID: 8774480
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
29. TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system.
Humbert L; Lebrun JJ
Cell Signal; 2013 Feb; 25(2):490-500. PubMed ID: 23085456
[TBL] [Abstract][Full Text] [Related]
30. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.
Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B
J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642
[TBL] [Abstract][Full Text] [Related]
31. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.
Jacquelot N; Enot DP; Flament C; Vimond N; Blattner C; Pitt JM; Yamazaki T; Roberti MP; Daillère R; Vétizou M; Poirier-Colame V; Semeraro M; Caignard A; Slingluff CL; Sallusto F; Rusakiewicz S; Weide B; Marabelle A; Kohrt H; Dalle S; Cavalcanti A; Kroemer G; Di Giacomo AM; Maio M; Wong P; Yuan J; Wolchok J; Umansky V; Eggermont A; Zitvogel L
J Clin Invest; 2016 Mar; 126(3):921-37. PubMed ID: 26854930
[TBL] [Abstract][Full Text] [Related]
32. Loss of beta-catenin expression associated with disease progression in malignant melanoma.
Kageshita T; Hamby CV; Ishihara T; Matsumoto K; Saida T; Ono T
Br J Dermatol; 2001 Aug; 145(2):210-6. PubMed ID: 11531781
[TBL] [Abstract][Full Text] [Related]
33. High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.
Yun SJ; Gimotty PA; Hwang WT; Dawson P; Van Belle P; Elder DE; Elenitsas R; Schuchter L; Zhang PJ; Guerry D; Xu X
Am J Surg Pathol; 2011 Feb; 35(2):235-42. PubMed ID: 21263244
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.
Espíndola MB; Corleta OC
World J Surg Oncol; 2008 Jun; 6():65. PubMed ID: 18570663
[TBL] [Abstract][Full Text] [Related]
35. Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression.
Malaponte G; Zacchia A; Bevelacqua Y; Marconi A; Perrotta R; Mazzarino MC; Cardile V; Stivala F
Oncol Rep; 2010 Jul; 24(1):81-7. PubMed ID: 20514447
[TBL] [Abstract][Full Text] [Related]
36. Are locoregional cutaneous metastases in melanoma predictable?
Borgstein PJ; Meijer S; van Diest PJ
Ann Surg Oncol; 1999; 6(3):315-21. PubMed ID: 10340893
[TBL] [Abstract][Full Text] [Related]
37. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination.
de Waal RM; van Altena MC; Erhard H; Weidle UH; Nooijen PT; Ruiter DJ
Am J Pathol; 1997 Jun; 150(6):1951-7. PubMed ID: 9176389
[TBL] [Abstract][Full Text] [Related]
38. Expression of vitamin D receptor decreases during progression of pigmented skin lesions.
Brożyna AA; Jozwicki W; Janjetovic Z; Slominski AT
Hum Pathol; 2011 May; 42(5):618-31. PubMed ID: 21292298
[TBL] [Abstract][Full Text] [Related]
39. The role of VEGF-C staining in predicting regional metastasis in melanoma.
Boone B; Blokx W; De Bacquer D; Lambert J; Ruiter D; Brochez L
Virchows Arch; 2008 Sep; 453(3):257-65. PubMed ID: 18679715
[TBL] [Abstract][Full Text] [Related]
40. Lymphatic invasion and the Shields index in predicting melanoma metastases.
Špirić Z; Erić M; Eri Ž
J Plast Reconstr Aesthet Surg; 2017 Nov; 70(11):1646-1652. PubMed ID: 28709916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
